Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate.
Prevention of respiratory syncytial virus (RSV) disease will implicate neonatal priming. However, neonatal antigen exposure frequently results into Th2-like responses, some of which are critical for formalin-inactivated RSV (FI-RSV)-associated lung immunopathology. Neonatal immunization of mice may thus represent a more stringent model of RSV-enhanced pathology than adults. Indeed, after RSV challenge, lung cell infiltration, lymphocyte activation, and eosinophilia were higher following neonatal compared with adult FI-RSV priming of BALB/c mice. Unexpectedly, similar findings were obtained with Al(OH)(3)-adsorbed live RSV. In contrast, neonatal priming with BBG2Na, a recombinant RSV subunit vaccine candidate, formulated in either Al(OH)(3) or TiterMax (a Th1-driving adjuvant) resulted in predominant Th2- or Th1-like responses, respectively, but never elicited lung immunopathology post-challenge. Importantly, our data emphasize that the induction of Th2-like responses by RSV subunit vaccines do not necessarily imply lung immunopathology.
Plotnicky
Hélène
H
Centre d'Immunologie Pierre Fabre, 5, Av Napoléon III, 74 164, St Julien en Genevois, France. helen.plotnicky@pierre-fabre.com
Siegrist
Claire-Anne
CA
Aubry
Jean-Pierre
JP
Bonnefoy
Jean-Yves
JY
Corvaïa
Nathalie
N
Nguyen
Thien Ngoc
TN
Power
Ultan F
UF
D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005557:Formaldehyde; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology* / Q000633:toxicity*; D015164:Vaccines, Inactivated / Q000276:immunology* / Q000633:toxicity
D000914:Antibodies, Viral; C472186:BBG2Na vaccine; D022261:Respiratory Syncytial Virus Vaccines; D015164:Vaccines, Inactivated; D005557:Formaldehyde